GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.

Ed Mahon reported this story while participating in the USC Annenberg Center for Health Journalism’s 2024 Data Fellowship and received engagement mentoring and funding. Spotlight PA is ...

Darker tints, like brown or amber, are common and work well for everyday use, REI reported. Brown offers a multitude of benefits that make it such a popular color. It helps protect your eyes by ...

Every year, tens of thousands of Americans die from opioid use. Ther were 82,000 opioid-involved overdose deaths in 2022, according to the US Centers for Disease Control and Prevention. The US gets 30 ...

The approval marks the first new class of pain medicine in more than two decades and offers a potential non-addictive alternative to opioids. "Today's approval is a historic milestone for the 80 ...

The approval marks the first new class of pain medicine in more than two decades and offers a potential non-addictive alternative to opioids. "Today's approval is a historic milestone for the 80 ...

led to a six percent decrease in daily opioid use. Between 2014 and 2019, opioid overdose deaths in Wisconsin rose by 46% according to data from the Wisconsin Department of Health Services.

Washington — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.

(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.